Heart failure (HF) is a common clinical syndrome characterized by high morbidity and frequent hospitalizations. HF is an independent and major risk factor for venous thromboembolism (VTE) and VTE occurring in patients with HF carries a worse prognosis. The present review will focus on short and long term role of anti-coagulants in prevention of venous thrombosis in HF patients. We will also be discussing the recently investigated and patented anti-coagulants which could have a role in this specific population.
Congestive heart failure, prevention, venous thromboembolism, CHRONIC ANTICOAGULATION, ORAL ANTICOAGULATION, PARENTERAL ANTICOAGULATION, Rivaroxaban, Dabigatran, Apixaban, MAGELLAN
Lehigh Valley Hospital and Health Network, Allentown, PA 18103, USA.